| Arthritis, Psoriatic
Hulio vs Renflexis
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Hulio vs Renflexis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRenflexis has a higher rate of injection site reactions vs Hulio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renflexis but not Hulio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hulio
Renflexis
At A Glance
SC injection
Every 1-2 weeks
TNF-alpha inhibitor
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
Indications
- Rheumatoid Arthritis
- Juvenile arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some Rheumatoid Arthritis patients not taking concomitant MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile arthritis Patients 2 years of age and older: 15 kg to <30 kg: 20 mg SC every other week; >=30 kg: 40 mg SC every other week.
Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years weighing 17 kg to <40 kg: 80 mg Day 1, 40 mg Day 15, 20 mg every other week; weighing >=40 kg: 160 mg Day 1, 80 mg Day 15, 40 mg every other week.
Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis vulgaris, Uveitis 80 mg SC initial dose, followed by 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks; pediatric patients >= 6 years with Crohn Disease or Ulcerative Colitis receive the same regimen.
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 6 weeks.
Contraindications
—
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of RENFLEXIS, or any murine proteins
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, abdominal pain, flu syndrome, hyperlipidemia, back pain, hypercholesterolemia, hypertension, hematuria, alkaline phosphatase increased.
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, severe hepatic reactions including acute liver failure.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis), hepatotoxicity, malignancies, severe infusion reactions
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction
Pharmacology
Adalimumab-fkjp is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammatory and immune responses in conditions including RA, JIA, PsA, AS, CD, UC, Ps, HS, and UV.
TNF-alpha antagonist; infliximab-abda is a chimeric IgG1kappa monoclonal antibody that neutralizes TNF-alpha by binding with high affinity to soluble and transmembrane forms of TNF-alpha, inhibiting receptor binding and suppressing downstream pro-inflammatory activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hulio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Renflexis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Hulio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Renflexis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hulio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Renflexis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hulio.
No savings programs available for Renflexis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RenflexisView full Renflexis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.